Last reviewed · How we verify
yellow fever vaccine (YFV)
Yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus through a live attenuated viral strain.
Yellow fever vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus through a live attenuated viral strain. Used for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic countries.
At a glance
| Generic name | yellow fever vaccine (YFV) |
|---|---|
| Sponsor | PATH |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
YFV contains a weakened live yellow fever virus (17D strain) that replicates in vaccinated individuals without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This generates protective immunity against natural yellow fever virus infection, with neutralizing antibodies typically appearing within 7–10 days and lasting for decades or life.
Approved indications
- Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic countries
Common side effects
- Headache
- Myalgia
- Fever
- Injection site reaction (pain, erythema, swelling)
- Fatigue
- Yellow fever vaccine-associated viscerotropic disease (YEL-AVD)
- Yellow fever vaccine-associated neurotropic disease (YEL-AND)
Key clinical trials
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- Trial of an Inactivated Yellow Fever Virus Vaccine (PHASE1)
- Durability of Vaccine Responses (PHASE4)
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL (PHASE3)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants (PHASE3)
- Booster Vaccine for Yellow Fever (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- yellow fever vaccine (YFV) CI brief — competitive landscape report
- yellow fever vaccine (YFV) updates RSS · CI watch RSS
- PATH portfolio CI